Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: An integrated analysis.
Katagiri, Hideaki Tohen, Mauricio Mc Donnell, David P. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Then enter the ‘name’ part of your Kindle email address below. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. are full-time employees and minor stockholders of Eli Lilly and Company.
Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders.
Partyka, Anna Jarosz, Jakub Wasik, Anna Jastrzębska-Więsek, Magdalena Zagórska, Agnieszka Pawłowski, Maciej and Wesołowska, Anna 2014.
The International Journal of Neuropsychopharmacology, Vol.
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
To send this article to your Kindle, first ensure [email protected] added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Note you can select to send to either the @free.or @variations. was an employee of Eli Lilly and Company while the study was conducted (until 2008) and has received honoraria from or consulted for Astra Zeneca, Bristol-Myers Squibb, Glaxo Smith Kline, Eli Lilly and Company, Johnson & Johnson, Sepracor, Otsuka, Merck, Sunovion, Forest, Lundbeck, Roche, Wyeth and Wiley Publishing; his spouse is a current employee and minor stockholder at Eli Lilly and Company.
Safety findings were consistent with the known safety profile of olanzapine. received grants and research support from Glaxo Smith Kline, Pfizer, Yoshitomi, Kyowa-Hakko, Astellas, Meiji and Otsuka; was a consultant for Eli Lilly and Company, Glaxo Smith Kline, Pfizer, Ono, Asahi-Kasei, Shionogi and Otsuka; and received honoraria from Eli Lilly and Company, Glaxo Smith Kline, Pfizer, Janssen, Meiji, Kyowa-Hakko, Dainippon-Sumitomo, Otsuka, Eisai, Taisho-Toyama and Astellas.